These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 15343199)

  • 1. Maintaining the nelfinavir trough concentration above 0.8 mg/L improves virologic response in HIV-1-infected children.
    Burger DM; Bergshoeff AS; De Groot R; Gibb D; Walker S; Tréluyer JM; Hoetelmans RM;
    J Pediatr; 2004 Sep; 145(3):403-5. PubMed ID: 15343199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and pharmacodynamics of nelfinavir administered twice or thrice daily to human immunodeficiency virus type 1-infected children.
    Gatti G; Castelli-Gattinara G; Cruciani M; Bernardi S; De Pascalis CR; Pontali E; Papa L; Miletich F; Bassetti D
    Clin Infect Dis; 2003 Jun; 36(11):1476-82. PubMed ID: 12766843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetics and pharmacodynamics of nelfinavir and its active metabolite M8 in HIV-1-infected children.
    Crommentuyn KM; Scherpbier HJ; Kuijpers TW; Mathôt RA; Huitema AD; Beijnen JH
    Pediatr Infect Dis J; 2006 Jun; 25(6):538-43. PubMed ID: 16732153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of nelfinavir in children: influencing factors and dose implications.
    Bergshoeff AS; Fraaij PL; van Rossum AM; Wolfs TF; Geelen SP; de Groot R; Burger DM
    Antivir Ther; 2003 Jun; 8(3):215-22. PubMed ID: 12924538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determination of indinavir and nelfinavir trough plasma concentration efficacy thresholds according to virological response in HIV-infected patients.
    Duval X; Peytavin G; Albert I; Bénoliel S; Ecobichon JL; Brun-Vézinet F; Mentré F; Leport C; Vildé JL
    HIV Med; 2004 Jul; 5(4):307-13. PubMed ID: 15236622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-HIV agents. Nelfinavir levels during pregnancy.
    TreatmentUpdate; 2004; 16(3):5-6. PubMed ID: 17216835
    [No Abstract]   [Full Text] [Related]  

  • 7. The long-term pharmacokinetics and safety of adding low-dose ritonavir to a nelfinavir 1,250 mg twice-daily regimen in HIV-infected patients.
    Justesen US; Hansen IM; Andersen AB; Klitgaard NA; Black FT; Gerstoft J; Mathiesen LR; Pedersen C
    HIV Med; 2005 Sep; 6(5):334-40. PubMed ID: 16156881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nelfinavir plasma concentrations are low during pregnancy.
    Nellen JF; Schillevoort I; Wit FW; Bergshoeff AS; Godfried MH; Boer K; Lange JM; Burger DM; Prins JM
    Clin Infect Dis; 2004 Sep; 39(5):736-40. PubMed ID: 15356791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected children.
    Rudin C; Burri M; Shen Y; Rode R; Nadal D; ;
    Pediatr Infect Dis J; 2008 May; 27(5):431-7. PubMed ID: 18382386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nelfinavir pharmacokinetics in HIV-infected children: a comparison of twice daily and three times daily dosing.
    Schuster T; Linde R; Wintergerst U; Funk MB; Kurowski M; Kreuz W; Hofmann D
    AIDS; 2000 Jul; 14(10):1466-8. PubMed ID: 10930171
    [No Abstract]   [Full Text] [Related]  

  • 11. Impact of human immunodeficiency virus type 1 subtypes on virologic response and emergence of drug resistance among children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 trial.
    Pillay D; Walker AS; Gibb DM; de Rossi A; Kaye S; Ait-Khaled M; Muñoz-Fernandez M; Babiker A
    J Infect Dis; 2002 Sep; 186(5):617-25. PubMed ID: 12195348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic drug monitoring of indinavir and nelfinavir to assess adherence to therapy in human immunodeficiency virus-infected children.
    van Rossum AM; Bergshoeff AS; Fraaij PL; Hugen PW; Hartwig NG; Geelen SP; Wolfs TF; Weemaes CM; De Groot R; Burger DM
    Pediatr Infect Dis J; 2002 Aug; 21(8):743-7. PubMed ID: 12192162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An MDR1-3435 variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children.
    Saitoh A; Singh KK; Powell CA; Fenton T; Fletcher CV; Brundage R; Starr S; Spector SA
    AIDS; 2005 Mar; 19(4):371-80. PubMed ID: 15750390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of highly active antiretroviral therapy with nelfinavir in vertically HIV-1 infected children: 3 years of follow-up. Long-term response to nelfinavir in children.
    Resino S; Larrú B; Maria Bellón J; Resino R; de José MI; Navarro M; Léon JA; Ramos JT; Mellado MJ; Muñoz-Fernández MA
    BMC Infect Dis; 2006 Jul; 6():107. PubMed ID: 16834769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic interaction between chemotherapy for non-Hodgkin's lymphoma and protease inhibitors in HIV-1-infected patients.
    Cruciani M; Gatti G; Vaccher E; Di Gennaro G; Cinelli R; Bassetti M; Tirelli U; Bassetti D
    J Antimicrob Chemother; 2005 Apr; 55(4):546-9. PubMed ID: 15728147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of nelfinavir in an HIV patient with renal insufficiency.
    Izzedine H; Diquet B; Launay-Vacher V; Jouan M; Theou N; Deray G
    AIDS; 1999 Oct; 13(14):1989. PubMed ID: 10513666
    [No Abstract]   [Full Text] [Related]  

  • 17. Intracellular accumulation of nelfinavir and its relationship to P-glycoprotein expression and function in HIV-infected patients.
    Hennessy M; Clarke S; Spiers JP; Kelleher D; Mulcahy F; Hoggard P; Back D; Barry M
    Antivir Ther; 2004 Feb; 9(1):115-22. PubMed ID: 15040543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low initial trough plasma concentrations of lopinavir are associated with an impairment of virological response in an unselected cohort of HIV-1-infected patients.
    Wateba MI; Billaud E; Dailly E; Jolliet P; Raffi F
    HIV Med; 2006 Apr; 7(3):197-9. PubMed ID: 16494635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical evaluation of the nelfinavir-rifabutin interaction in patients with tuberculosis and human immunodeficiency virus infection.
    Benator DA; Weiner MH; Burman WJ; Vernon AA; Zhao ZA; Khan AE; Jones BE; Sandman L; Engle M; Silva-Trigo C; Hsyu PH; Becker MI; Peloquin CA;
    Pharmacotherapy; 2007 Jun; 27(6):793-800. PubMed ID: 17542762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Elisa test for therapeutic monitoring of Nelfinavir in HIV-positive patients.
    Uglietti A; Genco F; Donadel E; Rinaldi S; Bastiani E; Maserati R; Meroni V
    New Microbiol; 2007 Jul; 30(3):318-20. PubMed ID: 17802918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.